Travel Vaccines Market in Top Seven Markets to Reach USD 2,224 Million by 2019, Expects GBI Research

07 Jun 2013 • by Natalie Aster

The travel vaccines market in the top seven markets (comprising the US, the UK, Spain, Italy, France, Germany and Japan) is expected to be worth $1,343m in 2012, having grown at a Compound Annual Growth Rate (CAGR) of 11% from 2007. The Year-on-Year (YoY) market growth was 6.3%, with revenue of $1,264m in 2011. It is expected to reach $2,224m by 2019, having grown at a CAGR of 7.5% from 2012.

The hepatitis A travel vaccines market in the top seven markets was worth $264m in 2012 and is expected to reach $423m by 2019 at a CAGR of 7%. The meningococcal travel vaccines market accounted for $225m in 2012 and is expected to reach $406m by 2019 at a CAGR of 8.8%. The Japanese Encephalitis (JE) travel vaccines market accounted for $234m in 2012 and is expected to reach $283m by 2019 at a CAGR of 2.7%.

According to the report “Travel Vaccines Market to 2019 - Hepatitis A, Japanese Encephalitis and Meningococcal Vaccine Segments to Drive Growth” by GBI Research, the global travel-vaccine pipeline appears very strong, with 18% of candidates in Phase II, 13% in Phase I, 11% in Phase III and 5% registration-filed. Vaccine companies manage their R&D portfolio by balancing investment between novel, innovative targets with the potential to have a major impact on human health; developing best-in-class approaches; and delivering the maximum value of approved vaccines through new indications and formulations.. Developing a new vaccine product is a costly, lengthy and uncertain process, and a new candidate can fail at any stage of the development process or fail to receive regulatory approval. However, vaccines’ ability to generate high revenues and profits despite being priced at a premium has proven attractive to existing players in the market and to big pharmaceutical companies, who have been watching development with interest.

Hepatitis A vaccines led the market in 2012 with a share of 20%, followed by JE vaccines and meningococcal vaccines with 17% each. Hepatitis A vaccines are commonly used prominent travel vaccines, and the increase in global tourist traffic has increased their use, in turn driving the market. Vaccines for hepatitis A provide immunity for approximately 15–20 years, rather than being lifelong, which is expected to drive future growth.

More information can be found in the report “Travel Vaccines Market to 2019 - Hepatitis A, Japanese Encephalitis and Meningococcal Vaccine Segments to Drive Growth” by GBI Research.